Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2743684 | 0.92 | TLR7 (0.59) | TLR7TLR8 | |
| SCHEMBL2743960 | 0.90 | TLR8 (0.61) | TLR7TLR8 | |
| SCHEMBL3871843 | 0.89 | TLR7 (0.55) | TLR7TLR8 | |
| SCHEMBL13937519 | 0.88 | TLR7 (0.59) | TLR7TLR8 | |
| SCHEMBL2743701 | 0.87 | TLR7 (0.55) | TLR7TLR8 | |
| SCHEMBL3869164 | 0.87 | TLR7 (0.71) | TLR7TLR8 | |
| SCHEMBL3869161 | 0.87 | TLR7 (0.71) | TLR7TLR8 | |
| SCHEMBL3876239 | 0.86 | TLR7 (0.55) | TLR7TLR8 | |
| SCHEMBL5356538 | 0.85 | TLR7 (0.68) | TLR7TLR8 | |
| SCHEMBL22359638 | 0.85 | TLR7 (0.65) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6756382-B2 | SECONDARY AMIDES SUCH AS N-(4-(4-AMINO-2-(2-METHOXYETHYL)-1H-IMIDAZO(4,5-C)QUINOLIN-1-YL)BUTYL)-1 -METHYL-5-OXO-2-PYRIDIN-3-YLPYRROLIDINE-3-CARBOXAMIDE; BIOSYNTHESIS OF CYTOKINES; PROPYLAXIS OF VIRAL DISEASES; IMMUNOLOGY MODULATORS | 3M INNOVATIVE PROPERTIES COMPANY | 2004-06-29 | — | — | US | claimed |
| US-20030144283-A1 | Amide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-07-31 | — | — | US | claimed |
| US-8110582-B2 | by administering immune response modifier compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-02-07 | — | — | US | disclosed |
| US-20090023722-A1 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-22 | — | — | US | disclosed |
| US-20090023722-A1 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-22 | — | — | US | disclosed |
| US-20090023722-A1 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-22 | — | — | US | disclosed |
| US-7393859-B2 | Amide substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7393859-B2 | Amide substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7393859-B2 | Amide substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| EP-1601365-A2 | PROPHYLACTIC TREATMENT OF UV-INDUCED EPIDERMAL NEOPLASIA | 3M Innovative Properties Company (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20040229897-A1 | Amide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-11-18 | — | — | US | disclosed |
| WO-2004078138-A2 | PROPHYLACTIC TREATMENT OF UV-INDUCED EPIDERMAL NEOPLASIA | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20040175336-A1 | Prophylactic treatment of UV-induced epidermal neoplasia | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-09 | — | — | US | disclosed |
| US-6756382-B2 | SECONDARY AMIDES SUCH AS N-(4-(4-AMINO-2-(2-METHOXYETHYL)-1H-IMIDAZO(4,5-C)QUINOLIN-1-YL)BUTYL)-1 -METHYL-5-OXO-2-PYRIDIN-3-YLPYRROLIDINE-3-CARBOXAMIDE; BIOSYNTHESIS OF CYTOKINES; PROPYLAXIS OF VIRAL DISEASES; IMMUNOLOGY MODULATORS | 3M INNOVATIVE PROPERTIES COMPANY | 2004-06-29 | — | — | US | disclosed |
| US-20030144283-A1 | Amide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229897-A1 | Amide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 30/4885TLR8 72/4885 |
| US-20090023722-A1 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | IFNG, IRF3, EIF2AK2 | TLR7 30/4885TLR8 72/4885 |
| US-20030144283-A1 | Amide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 30/4885TLR8 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.